All In Biotech

Drug Trial Radar · NCT07784101

A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL)

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2032

Study completion Dec 2033

Sponsor

Sponsor type
Industry
First posted
Aug 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).

Conditions

  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Interventions

  • ICP-248Drug

    Administered orally

  • PirtobrutinibDrug

    Administered orally

  • OrelabrutinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) as assessed by Independent Review Committee (IRC).Time frame: 6 years

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Xinqiao Hospital of Army Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

    Nanjing, Jiangsu, China

  • The first Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xian, Shanxi, China

  • The First Affiliated Hospital of the PLA Air Force Military Medical University (Xijing Hospital)

    Xian, Shanxi, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.